---
title: "Sellas’ galinpepimut-S cut mortality by 41% in Phase 3 AML trial, company reports"
id: "stat-news-2-stat-sellas-experimental-blood-cancer-immunotherapy-reduced-risk-of-death-in"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-2-stat-sellas-experimental-blood-cancer-immunotherapy-reduced-risk-of-death-in"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/?utm_campaign=rss"
published_at: "2026-11-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Sellas’ galinpepimut-S cut mortality by 41% in Phase 3 AML trial, company reports
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-2-stat-sellas-experimental-blood-cancer-immunotherapy-reduced-risk-of-death-in
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/?utm_campaign=rss)
- **Published At:** 2026-11-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Sellas Life Sciences reported that its immunotherapy **galinpepimut-S** lowered the risk of death by 41% versus standard care in patients with advanced **acute myeloid leukemia** (AML). - The company said the outcome met the primary objective of a **Phase 3** clinical trial, according to the source. The trial achievement was described as the study’s main goal. - The reporting outlet noted the author had earlier predicted the therapy would fail to prolong survival, and acknowledged being wrong in light of the new company announcement. - The source article did not provide trial methodology details such as randomization scheme, control regimen specifics, dosing, or eligibility criteria. - The STAT piece did not report sample size, statistical measures (p-values, confidence intervals), duration of follow-up, or secondary endpoint results. - Safety and adverse-event data were not included in the source material; the article did not describe tolerability or treatment-related mortality. - Regulatory plans, next steps for approval, or independent expert commentary were not reported in the source article. - The available information is limited to the company’s announcement that the **Phase 3** trial met its primary endpoint with a 41% reduction in risk of death for advanced AML patients.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/?utm_campaign=rss) [education](https://www.statnews.com/topic/education/) [research](https://www.statnews.com/topic/research/) [FDA](https://www.statnews.com/topic/fda/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Trust in Science](https://www.statnews.com/trust-in-science/) * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Madness 2027](https://www.statnews.com/feature/stat-madness/apply/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) China's Biotech Powerhouse 25 We ranked the 25 most valuable publicly traded Chinese drugmakers [ See the list ](https://www.statnews.com/china-biotech-index-powerhouse-25/) [STAT Plus](https://www.statnews.com/stat-plus/)Opinion[Adam’s Take](https://www.statnews.com/category/adams-take/) # Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial ## The unexpected result is good news for patients with acute myeloid leukemia * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/17/sellas-blood-cancer-immunotherapy-succeeds-clinical-trial/?utm_campaign=rss) ![histopathology from patient with acute myeloid leukemia \(AML\)](https://www.statnews.com/wp-content/uploads/2022/12/19467-645x645.jpg) Histopathology from patient with acute myeloid leukemia.CDC ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Nov. 17, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of [ Adam’s Biotech Scorecard](https://www.statnews.com/category/adams-biotech-scorecard/), a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology. ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") adam.feuerstein@statnews.com Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. It looks like I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy. On Tuesday, Sellas said the therapy, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia (AML) — an outcome that achieved the main goal of a Phase 3 clinical trial, the company said. Advertisement Related Story ![](https://www.statnews.com/wp-content/uploads/2022/06/AdamsTake_Illustration_MollyFerguson_061322-768x432.jpg) ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [STAT Plus: A Sellas immunotherapy study, long delayed, will end in failure](https://www.statnews.com/2026/09/17/sellas-immunotherapy-study-acute-myeloid-leukemia/) In a [column published in September](https://www.statnews.com/2026/09/17/sellas-immunotherapy-study-acute-myeloid-leukemia/), I predicted galinpepimut would fail to prolong survival in the Phase 3 study. [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [Clinical trials](https://www.statnews.com/topic/clinical-trials/), [FDA](https://www.statnews.com/topic/fda/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/adam-f-avatar-small2-80x80.png) [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 1. [](https://x.com/adamfeuerstein "X") 2. Senior Writer, Biotech 1. [](https://x.com/adamfeuerstein "X") 2. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast [The Readout Loud](https://www.statnews.com/category/readout-loud/) and author of the newsletter [Adam’s Biotech Scorecard.](https://www.statnews.com/signup/scorecard/) You can reach Adam on Signal at stataf.54. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2024/03/Biotech-Scorecard-Logo-NoSTAT-640x290.png) ### STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_331634765-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [After death in gene therapy trial for a brain disease, progress is reported ](https://www.statnews.com/2026/11/17/capsida-gene-therapy-trial-death-follow-up-investigation/) 2. ![](https://www.statnews.com/wp-content/uploads/2017/01/AP80889059-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs](https://www.statnews.com/2026/11/16/judge-rejects-visa-limits-international-researchers-upholds-duration-of-status-policy/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_587333568_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In a win for MAHA, FDA creates new regulatory category for the supplement NAC](https://www.statnews.com/2026/11/16/fda-proposes-new-category-supplement-nac/) 4. ![](https://www.statnews.com/wp-content/uploads/2025/08/AP24163743721308-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [New Trump regulation promises to crush ‘fraudsters.’ All the savings come from Medicare Advantage](https://www.statnews.com/2026/11/16/cms-proposes-more-agressive-audits-medicare-advantage-crush/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_331634765-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [After death in gene therapy trial for a brain disease, progress is reported ](https://www.statnews.com/2026/11/17/capsida-gene-therapy-trial-death-follow-up-investigation/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/10/STATatHLTH_Wordpress_CalendarImage-80x80.jpg) STAT@hlth. A Dose of Reality on EHRs and AI In-person Nov 18 ](https://www.statnews.com/event/stathlth-a-dose-of-reality-on-ehrs-and-ai/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/BTE2027_Wordpress_CalendarImage-80x80.jpg) 2027 Breakthrough Summit East New York City, NY Mar 18 ](https://www.statnews.com/event/2027-stat-breakthrough-summit-east/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_391451620_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug](https://www.statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-she-was-fired-for-complaining-about-marketing-of-mounjaro-diabetes-drug/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_6400491-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA warns GLP-1 drugs carry potential risk of rare eye condition](https://www.statnews.com/2026/11/09/glp-1-drugs-potential-risk-rare-eye-condition-naion-fda/) 3. ![](https://www.statnews.com/wp-content/uploads/2019/09/AP_060324030695-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves novel Bayer drug to reduce recurrence of stroke](https://www.statnews.com/2026/11/09/cardiovascular-stroke-recurrence-bayer-drug-fda-approval/) 4. ![](https://www.statnews.com/wp-content/uploads/2024/09/GettyImages-1237273640-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics](https://www.statnews.com/2026/11/15/fda-rejects-ivonescimab-lung-cancer-treatment-summit-therapeutics/) 5. ![](https://www.statnews.com/wp-content/uploads/2017/01/AP80889059-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs](https://www.statnews.com/2026/11/16/judge-rejects-visa-limits-international-researchers-upholds-duration-of-status-policy/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard November 12, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What to know about Biogen’s big lupus study readout ](https://www.statnews.com/2026/11/12/biogen-lupus-litifilimab-what-to-know/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard November 12, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem ](https://www.statnews.com/2026/11/12/alnylam-amvuttra-heart-drug-growth/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard November 5, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: A closer look at ProMis Neurosciences and its Alzheimer’s drug ](https://www.statnews.com/2026/11/05/promis-neurosciences-alzheimers-disease-acumen-vertex-kidney-drug/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard October 29, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Vertex kidney disease drug scrutinized for infection risk ](https://www.statnews.com/2026/10/29/biotech-news-vertex-kidney-disease-drug-scrutinized-for-infection-risk/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Adam's Biotech Scorecard Adam's Biotech Scorecard October 15, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: On Wall Street, there’s trouble stirring for biotech ](https://www.statnews.com/2026/10/15/wall-street-biotech-trouble-stirring/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) #### Subscriber Picks 1. ### [ A new tactic in the war over out-of-network bills: Health care providers are suing employers ](https://www.statnews.com/2026/11/11/no-surprises-act-phi-health-air-ambulance-sues-employers/) By [Bob Herman](https://www.statnews.com/staff/bob-herman/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: As Epic’s dominance grows, its iron grip is choking innovation in health technology ](https://www.statnews.com/2026/10/28/epic-systems-ehr-dominance-health-tech-antitrust-scrutiny/) By [Casey Ross](https://www.statnews.com/staff/casey-ross/) and [Brittany Trang](https://www.statnews.com/staff/brittany-trang/) 3. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What to know about Biogen's big lupus study readout ](https://www.statnews.com/2026/11/12/biogen-lupus-litifilimab-what-to-know/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 4. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug ](https://www.statnews.com/pharmalot/2026/11/10/former-lilly-rep-claims-she-was-fired-for-complaining-about-marketing-of-mounjaro-diabetes-drug/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 5. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plu
## Related Clinical Research

- [Heidi Overton FDA Nomination Withdrawn; Merck Stops Nemtabrutinib Program](https://medichelpline.com/clinical-feed/stat-news-2-stat-pharmalittle-we-re-reading-about-overton-fda-nomination-being-yanked-a.md)
- [Flagship opens biotech-creation outpost in the U.K.; sector updates on Isomorphic and Sellas](https://medichelpline.com/clinical-feed/stat-news-1-stat-flagship-opens-biotech-creation-outpost-in-the-u-k.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.